Skip to main content

Language(s) Spoken

English; Gujarati

Joined Kelsey-Seybold

February 2018

Accepting New Patients?

Yes

Professional B​​ackground

Niravkumar Naik, M.D., is a Hematology/Oncology specialist. He earned his medical degree in 2005 at St. George’s University School of Medicine - Grenada, West Indies. In 2009, he completed his residency in Internal Medicine at the Medical College of Wisconsin in Milwaukee. He completed his fellowship training in Hematology/Oncology in 2012, also at the Medical College of Wisconsin. He is board-certified by the American Board of Internal Medicine in the subspecialties of Hematology and Medical Oncology.

After completing his education and training, Dr. Naik was a Hematology/Oncology staff physician from 2012-2016 at Wheaton Franciscan Healthcare in Milwaukee. Prior to joining Kelsey-Seybold, he was a Hematology/Oncology staff physician at Oncology Specialists of Charlotte in North Carolina.

Professional Ass​​ociations

Dr. Naik is a member of the American Society of Hematology and the American Society of Clinical Oncology. 

Hobbies and Intere​sts

Dr. Naik enjoys spending time with friends and family, and watching college football. He enjoys traveling to other countries and experiencing different foods and other cultures.

Fun Fa​cts

The best advice given to Dr. Naik is to “spend time with your children.” His guilty pleasure is trying exotic foods.
 
Dr. Naik was born in Zambia and moved to the United States when he was 11. He always wanted to be a physician. Growing up in Africa where there is limited access to healthcare inspired him to pursue a career in medicine.
 

​Cancer is a complex diagnosis.  I truly believe that understanding the individual needs of each patient and incorporating a team-based, multidisciplinary treatment approach is important in providing excellent care to our patients. 

​​

​​​​​​​​​By Phone

Our Contact Center is here to serve you, 24 hours a day, 7 days a week.

713-442-1080​​
​​ ​

Awards & Recognitions

​Res​earch

  • W​heaton Franciscan Healthcare, Protocol NLG2101 Phase II Study of Docetaxel in Combination with Indoximod in Metastatic Breast Cancer. Sub-Investigator.
  • Wheaton Franciscan Healthcare, SWOG1202 Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer, Sub-Investigator.
  • Wheaton Franciscan Healthcare, Protocol 20120166 Phase IIIB, Multicenter, Open-label, Single arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects with Unresected Stage IIIB or  IVM1c Melanoma, Sub-Investigator.
  • Department of Hematology/Oncology – Medical College of Wisconsin, Improving breast cancer patient adherence to adjuvant endocrine therapy through Pharmacist interventions via mail-order services                                            Principal investigator: John Charlson, MD​
  • Department of Molecular Biochemistry – University of Georgia, Center for Biological Resource Recovery – Student Research Assistant Director, Lars Ljungdahl, PhD (January 1998 to December 1998) Performed laboratory experiments related to the use of anaerobic fungi in the degradation of cellulose and other complex carbohydrates
  • Department of Microbiology and Immunology – Morehouse School of Medicine – Research Internship Director, Caroline Genco, PhD (June 1996 to September 1996), Performed experimental research on the mechanism of iron transport in N. gonorrhoeae and its significance in expression of virulence factors
 

A​bstracts

  • American ​Society of Hematology, The impact of pre-transplant co-morbidities on the outcome of autologous hematopoietic cell transplantation in multiple myeloma, On-line abstract, ASH 2011​